CELG

5 Biotech Stocks That Are Getting Battered Too Hard for Comfort

By Anthony Mirhaydari, InvestorPlace Market Strategist
A number of technical indicators are weakening or flashing warning signals for biotech stocks, and these five stand out as some of the most vulnerable.

Buy the Dip in Amgen, Inc. While Wall Street Fears It

By Nicolas Chahine, InvestorPlace Contributor
Biotech falling knives like Amgen are notoriously dangerous, but AMGN stock has value against which I am willing to bet bullish.

Celgene Corporation (CELG) Plummets After 2020 Guidance Cut

By William White, InvestorPlace Writer
Celgene (CELG) stock was hit hard on Thursday following the release of its earnings report for the third quarter of 2017.

Weakening Earnings Visibility Downgrades Celgene (CELG) to Hold

By Portfolio Grader
Celgene Corp (NASDAQ:CELG) is classified as a constituent of the 345 company Biotechnology GICS industry group, which is a segment of the 782 company GICS Health Care sector. The market value of CELG is $94.9 billion which places it in the top 10% of its industry group. The ranking for CELG by Portfolio Grader places it 128 among the 345 companies in this industry group, putting it in the second quartile; in the top half of the sector with a ranking of 308 among the 782 companies in the sector, and number 2,166 in the nearly 5,000 company Portfolio Grader universe.

Catch This Falling Knife — Go Long Celgene Corporation

By Nicolas Chahine, InvestorPlace Contributor
Pharma stock falling knives are the scariest to catch. But this reaction to the Celgene headline is overdone. Catch CELG but with caution.

3 Stocks to Watch on Friday: Celgene Corporation (CELG), Intuitive Surgical, Inc. (ISRG) and Skechers USA Inc (SKX)

By Karl Utermohlen, InvestorPlace Writer
Celgene (CELG) won't start phase 3 trial for Crohn's disease drug, while Intuitive Surgical (ISRG) and Skechers (SKX) reports on earnings.

Celgene’s (CELG) Upgraded to Buy

By Portfolio Grader
Celgene Corp (NASDAQ:CELG) is one of the 783 companies in the GICS Health Care sector, and a member of the 344 company Biotechnology GICS industry group within this sector. CELG's market value is $106.7 billion which places it in the top decile in its industry group. Portfolio Grader's current ranking for CELG puts it 62 among the 344 companies in this industry group, giving it a well above-average position; in the top quartile of the sector with a ranking of 168 among the 783 companies in the sector, and number 1,246 in the nearly 5,000 company Portfolio Grader universe.

Celgene (CELG) Stock Upgraded to Buy from a Hold

By Portfolio Grader
Celgene Corp (NASDAQ:CELG) is ranked as a Buy using the stock evaluator from Portfolio Grader, which incorporates Louis Navellier's investing methodology. CELG has been upgraded from a Hold to a Buy in the last week.

No Side Effects to This Bullish Trade on Celgene Corporation (CELG) Stock

By Nicolas Chahine, InvestorPlace Contributor
Biotech names like Celgene make for scary falling knives. Catching CELG stock can be hazardous to your folio -- but not if you use this play.

Immunize Juno Therapeutics Inc (JUNO) Stock With This Trade

By Chris Tyler, InvestorPlace Contributor
JUNO stock has a lot going for it, but a bullish position looks a good deal better when fully-immunized with an options hedge.

3 Biotech Stocks That Are Just Getting Started

By Tyler Craig, Tales of a Technician
Biotech stocks are leading the charge in this bull market. And last week's drop is a golden opportunity for buying these three beauties.

5 of the Toughest Stocks to Withstand a Downturn

By Harriet Lefton, Writer, TipRanks
These downturn-proof stocks to buy are much tougher than most on the market. Here's why each are among the toughest stocks to own.

SPDR S&P Biotech (ETF) (XBI): The Quick Guide to XBI

By Todd Shriber, InvestorPlace Contributor
Biotechnology investors have turned the equal-weight SPDR S&P Biotech ETF (XBI) into one of the largest sector plays. Is it right for you?

Supercharge Your Portfolio With Amgen, Inc. (AMGN) Stock

By Nicolas Chahine, InvestorPlace Contributor
Wall Street goes on buying sprees into the biotech sector. Take advantage of this run to profit from red hot AMGN Stock. It's headed higher.

5 Biotech Stocks That Are Breaking Higher

By Anthony Mirhaydari, InvestorPlace Market Strategist
Biotech stocks are surging amid M&A speculation after Gilead agreed to buy Kite Pharma. And these biotechs are moving higher in response.

3 Biopharma Picks for Big Rewards with Less Risk

By Luce Emerson, InvestorPlace Contributor
Investors may initially shy away from biopharma companies given the complexity of the science, but these 3 have a lot going for them.

Trade of the Day: Celgene Corporation (CELG) Stock Flashing Buy Signals

By Serge Berger, InvestorPlace Contributor
CELG stock bounced off a critical technical support level and Celgene now offers traders a well-defined reward to risk trade to the upside.

3 Large-Cap Biotech Stocks to Scrape From the Selloff

By Chris Tyler, InvestorPlace Contributor
Large-cap biotech stocks like Regeneron, Celgene and Amgen are offering value both on and off the price chart. Here's how to profit.

Trade of the Day: Celgene Corporation (CELG)

By John Jagerson and Wade Hansen
The company failed to boost its full-year guidance for 2017, and this seems to have led to a bit of profit-taking, which took the stock back down to support at $134. We expect this support level to hold and for CELG to revisit its recent highs.
Load More